Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
44
BCYC Quote, Financials, Valuation and Earnings
Last price:
$7.06
Seasonality move
:
-0.27%
Day range:
$6.85 - $7.22
52-week range:
$6.03 - $13.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.11x
P/B ratio:
1.09x
Volume:
168.6K
Avg. volume:
237.7K
1-year change:
-46.07%
Market cap:
$485.6M
Revenue:
$35.3M
EPS (TTM):
-$3.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc
|
$7.1M | -$0.94 | -27.61% | -7.34% | $21.50 |
|
AUTL
Autolus Therapeutics Plc
|
$24.1M | -$0.41 | 199.85% | -6.42% | $9.30 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
DBVT
DBV Technologies SA
|
$1.2M | -$0.22 | -- | -86.12% | $39.69 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -75.07% | $3.45 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc
|
$7.00 | $21.50 | $485.6M | -- | $0.00 | 0% | 17.11x |
|
AUTL
Autolus Therapeutics Plc
|
$1.39 | $9.30 | $369.9M | -- | $0.00 | 0% | 7.22x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.25 | $17.94 | $1.9M | -- | $0.00 | 0% | 0.73x |
|
DBVT
DBV Technologies SA
|
$22.87 | $39.69 | $625.8M | -- | $0.00 | 0% | -- |
|
MREO
Mereo BioPharma Group Plc
|
$0.49 | $3.45 | $78.2M | -- | $0.00 | 0% | 153.66x |
|
NCNA
NuCana Plc
|
$3.10 | $104.00 | $12.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 1.504 | 1.21% | 9.36x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.671 | 5.85% | 1.41x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.603 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Bicycle Therapeutics Plc vs. Competitors
-
Which has Higher Returns BCYC or AUTL?
Autolus Therapeutics Plc has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of -373.3%. Bicycle Therapeutics Plc's return on equity of -34.37% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About BCYC or AUTL?
Bicycle Therapeutics Plc has a consensus price target of $21.50, signalling upside risk potential of 207.14%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.30 which suggests that it could grow by 569.07%. Given that Autolus Therapeutics Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Autolus Therapeutics Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is BCYC or AUTL More Risky?
Bicycle Therapeutics Plc has a beta of 1.524, which suggesting that the stock is 52.42% more volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.012, suggesting its more volatile than the S&P 500 by 101.185%.
-
Which is a Better Dividend Stock BCYC or AUTL?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or AUTL?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Bicycle Therapeutics Plc's net income of -$58.7M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 17.11x versus 7.22x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc17.11x -- $11.7M -$58.7M AUTLAutolus Therapeutics Plc7.22x -- $21.1M -$78.6M
-
Which has Higher Returns BCYC or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of --. Bicycle Therapeutics Plc's return on equity of -34.37% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About BCYC or BDRX?
Bicycle Therapeutics Plc has a consensus price target of $21.50, signalling upside risk potential of 207.14%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 7804.5%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is BCYC or BDRX More Risky?
Bicycle Therapeutics Plc has a beta of 1.524, which suggesting that the stock is 52.42% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock BCYC or BDRX?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or BDRX?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Bicycle Therapeutics Plc's net income of -$58.7M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 17.11x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc17.11x -- $11.7M -$58.7M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns BCYC or DBVT?
DBV Technologies SA has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of --. Bicycle Therapeutics Plc's return on equity of -34.37% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About BCYC or DBVT?
Bicycle Therapeutics Plc has a consensus price target of $21.50, signalling upside risk potential of 207.14%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 73.26%. Given that Bicycle Therapeutics Plc has higher upside potential than DBV Technologies SA, analysts believe Bicycle Therapeutics Plc is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 DBVTDBV Technologies SA4 0 1 -
Is BCYC or DBVT More Risky?
Bicycle Therapeutics Plc has a beta of 1.524, which suggesting that the stock is 52.42% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.
-
Which is a Better Dividend Stock BCYC or DBVT?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or DBVT?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are larger than DBV Technologies SA quarterly revenues of --. Bicycle Therapeutics Plc's net income of -$58.7M is lower than DBV Technologies SA's net income of -$33M. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 17.11x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc17.11x -- $11.7M -$58.7M DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns BCYC or MREO?
Mereo BioPharma Group Plc has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of -2923.31%. Bicycle Therapeutics Plc's return on equity of -34.37% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About BCYC or MREO?
Bicycle Therapeutics Plc has a consensus price target of $21.50, signalling upside risk potential of 207.14%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.45 which suggests that it could grow by 600.69%. Given that Mereo BioPharma Group Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Mereo BioPharma Group Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 MREOMereo BioPharma Group Plc4 2 0 -
Is BCYC or MREO More Risky?
Bicycle Therapeutics Plc has a beta of 1.524, which suggesting that the stock is 52.42% more volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.214%.
-
Which is a Better Dividend Stock BCYC or MREO?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or MREO?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. Bicycle Therapeutics Plc's net income of -$58.7M is lower than Mereo BioPharma Group Plc's net income of -$7M. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 17.11x versus 153.66x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc17.11x -- $11.7M -$58.7M MREOMereo BioPharma Group Plc153.66x -- -- -$7M
-
Which has Higher Returns BCYC or NCNA?
NuCana Plc has a net margin of -503.67% compared to Bicycle Therapeutics Plc's net margin of --. Bicycle Therapeutics Plc's return on equity of -34.37% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About BCYC or NCNA?
Bicycle Therapeutics Plc has a consensus price target of $21.50, signalling upside risk potential of 207.14%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 670867.74%. Given that NuCana Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe NuCana Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics Plc6 4 0 NCNANuCana Plc0 1 0 -
Is BCYC or NCNA More Risky?
Bicycle Therapeutics Plc has a beta of 1.524, which suggesting that the stock is 52.42% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock BCYC or NCNA?
Bicycle Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or NCNA?
Bicycle Therapeutics Plc quarterly revenues are $11.7M, which are larger than NuCana Plc quarterly revenues of --. Bicycle Therapeutics Plc's net income of -$58.7M is lower than NuCana Plc's net income of -$378.9K. Notably, Bicycle Therapeutics Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics Plc is 17.11x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics Plc17.11x -- $11.7M -$58.7M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
52
CVLT alert for Jan 27
Commvault Systems, Inc. [CVLT] is down 31.22% over the past day.
Buy
73
BNAI alert for Jan 27
Brand Engagement Network, Inc. [BNAI] is down 16.85% over the past day.
Buy
71
SANM alert for Jan 27
Sanmina Corp. [SANM] is down 21.58% over the past day.
